SCYNEXIS, Inc.

SCYX

US8112922005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
2.35 ^USD	+4.91%		-15.16%	+5.38%

05-08	Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M	MT
05-08	SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

SCYNEXIS, Inc. Announces Resignation of Yves J. Ribeill from Board of Directors

March 21, 2016 at 12:18 pm

On March 16, 2016, Yves J. Ribeill, Ph.D. notified SCYNEXIS, Inc. that he had resigned from the SCYNEXIS
Board of Directors effective immediately.

Latest news about SCYNEXIS, Inc.

Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M	05-08	MT
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	04-09	CI
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference	01-29	CI
SCYNEXIS Amends License Agreement With GlaxoSmithKline Intellectual Property; Shares Drop Premarket	01-03	MT
Earnings Flash (SCYX) SCYNEXIS Reports Q3 Revenue $1.8M	11-13	MT
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology	24/10/23	CI
SCYNEXIS Recalls Two Lots of Brexafemme Due to Potential for Cross Contamination with Non-Antibacterial Drug Substance	28/09/23	MT
SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance	28/09/23	CI
Sector Update: Health Care Stocks Advancing Late Afternoon	25/09/23	MT
Top MIdday Decliners	25/09/23	MT
Ladenburg Thalmann Cuts SCYNEXIS Price Target to $7.50 From $15, Maintains Buy Rating	25/09/23	MT
SCYNEXIS Recalls Brexafemme on Cross Contamination Risk; Shares Fall	25/09/23	MT
Earnings Flash (SCYX) SCYNEXIS Posts Q2 Revenue $131.5M	14/08/23	MT
SCYNEXIS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
SCYNEXIS Says New Drug Application for Vulvovaginal Candidiasis Treatment Accepted for Review in China	20/07/23	MT
SCYNEXIS, Inc.(NasdaqGM:SCYX) dropped from Russell Microcap Value Index	23/06/23	CI
SCYNEXIS, Inc.(NasdaqGM:SCYX) dropped from Russell 3000E Value Index	23/06/23	CI
Scynexis Says $25 Million Performance-Based Development Milestone Achieved as Part of GSK License Deal	21/06/23	MT
Scynexis Closes Exclusive Brexafemme License Deal With GSK	12/05/23	MT
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Guggenheim Adjusts Price Target on SCYNEXIS to $9 From $8, Maintains Buy Rating	03/04/23	MT
Earnings Flash (SCYX) SCYNEXIS Posts Q4 Revenue $1.4M	31/03/23	MT

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Sector

Pharmaceuticals

Calendar

19/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for SCYNEXIS, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.35 USD

Average target price

6.875 USD

Spread / Average Target

+192.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SCYNEXIS, INC.	+5.38%	88.78M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Pharmaceuticals

SCYNEXIS, Inc. Announces Resignation of Yves J. Ribeill from Board of Directors

Latest news about SCYNEXIS, Inc.

Chart SCYNEXIS, Inc.

Company Profile

Income Statement Evolution

Ratings for SCYNEXIS, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals